Startups
Vaccine Company
Vaccine Company develops next-generation vaccines using In Vivo Nanoparticle technologies that combine mRNA and virus-like-particle approaches to display multiple antigens and seek durable immune responses while reducing manufacturing complexity. Its lead five-antigen Epstein-Barr virus vaccine was ready for Phase 1 development when the company announced its sale to Eli Lilly in May 2026; preventing EBV could also reduce associated long-term neurological and oncological disease. Founded in 2022 by ARCH Venture Partners, with Luma Group joining as a co-founding investor, the company is now included in Lilly’s subsidiary portfolio. It also received an ARPA-H research award for flavivirus vaccines.
Founded 2022
Team
Abigail PowellDirector, Protein Sciences (published Stanford alumni biography) |
Eric JensenCorporate Secretary (2024 filing; historical) |
 Jay MarkowitzBoard Director (2022 annual report filed 2024; historical) |
John MarkelsFormer Chief Executive Officer & Board Director |
Julie LedgerwoodChief Medical Officer (2024 filing); ARPA-H Principal Investigator |
 Luciana BorioBoard Director (2024 filing; before acquisition) |
Payton WeidenbacherDirector, Protein and Virus Sciences (published Stanford alumni biography) |
Peter KimBoard Director (2024 filing; before acquisition) |
 Robert NelsenBoard Director (2022 annual report filed 2024; historical) |
Sonya BernsteinChief Financial Officer (2024 filing; before acquisition) |
Susan SilbermannChief Executive Officer & Board Director (before 2026 acquisition) |